H1N1 COUNTERMEASURES STRATEGY AND ... - PHE Home

NBSB Pandemic Influenza Working Group
Detailed Report
Day 2 - June 19, 2009
Diagnostics – Strategies for Use of Diagnostics in a Pandemic
8:00-8:15 Background Andrew Pavia
8:15-8:35 Diagnostics and influenza pandemics: Dan Jernigan
Lessons learned and future prospects
8:35-8:55 FDA perspective: Diagnostics for Sally Hojvat
pandemics and biodefense
8:55-9:15 Influenza Diagnostic Algorithm and Dan Harms
Identification Capability within DoD
Clinical Laboratories.
9:15-10:15 Panel Discussion Steve Cantrill
Anthony Fiore
Dan Jernigan
Sally Hojvat
Dan Harms
Questions to consider:
What is the optimal role of diagnostic testing for public health surveillance
during a pandemic? Is it appropriate to have different goals during different phases,
or is it a compromise based on limited capacity?
What are the benefits of comprehensive testing at large medical centers? Is testing
of hospitalized patients an important part of surveillance? Are there other models of
sentinel surveillance?
What might be the benefits of an accurate point of care test? What degree of accuracy
would be needed? Do these hypothesized benefits need to be tested?
How can diagnostic testing be integrated into community mitigation efforts (for example
for school closure, voluntary quarantine, post exposure prophylaxis)
Public health laboratories have very limited capacity. Do they need to be supplemented
by other sources? Should restoring public health capacity take precedence over using
clinical capacity?
10:15-10:30 Break
Antivirals
10:30-11:10 I. Antiviral drugs in the development Fred Hayden
II. What do we need from antiviral drugs
11:10-11:30 GSK Zanamivir Strategy and Response Judith Ng-Cashin
to Novel H1N1
11:30-11:50 Advanced Clinical Development of Peramivir William Sheridan
3